Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose-Reference-Cited by-同舟云学术

Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose

Published:2016-06-10 Issue:10 Volume:56 Page:1243-1253
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Krieter Philip¹,Chiang Nora¹,Gyaw Shwe¹,Skolnick Phil¹,Crystal Roger²,Keegan Fintan³,Aker Julie⁴,Beck Melissa⁴,Harris Jennifer⁴

Affiliation:

1. National Institute on Drug Abuse; National Institutes of Health; Bethesda MD USA

2. Lightlake Therapeutics; New York NY USA

3. Adapt Pharma, Ltd; Dublin Ireland

4. Concentrics Research; Indianapolis IN USA

Funder

Lightlake Therapeutics, Adapt Pharma, and NIDA contracts

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference37 articles.

1. Trends in opioid analgesic abuse and mortality in the United States;Dart;N Engl J Med.,2015

2. Opioid overdose prevention programs providing naloxone to laypersons-United States, 2014;Wheeler;Morbid Mortal Weekly Rep (MMWR),2015

3. Increases in drug and opioid overdose deaths-United States, 2000-2014;Rudd;Morbid Mortal Weekly Rep (MMWR),2016

4. Substance Abuse and Mental Health Services Administration Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits Rockville, MD Substance Abuse and Mental Health Services Administration 2013

5. Relationship between nonmedical prescription-opioid use and heroin use;Compton;N Engl J Med,2016

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanism of the first and second peaks in epinephrine pharmacokinetics over time;2023-12-20

2. A study protocol for a European, mixed methods, prospective, cohort study of the effectiveness of naloxone administration by community members, in reversing opioid overdose: NalPORS;BMC Public Health;2023-08-24

3. Pharmacokinetic Properties of an FDA‐approved Intranasal Nalmefene Formulation for the Treatment of Opioid Overdose;Clinical Pharmacology in Drug Development;2023-07-27

4. Re-examining Naloxone Pharmacokinetics After Intranasal and Intramuscular Administration Using the Finite Absorption Time Concept;European Journal of Drug Metabolism and Pharmacokinetics;2023-06-02

5. Paraventricular Nucleus of the Hypothalamus Oxytocin and Incubation of Heroin Seeking;Neuroendocrinology;2023